

dimethylarginine)

Patient Information		Specimen 1	Specimen Information			Client Information	
			Cardio IO	$\mathbf{Q}^{\mathbb{R}}$			
	Cui	Current		Risk/Reference Interval			Historical
Test Name	Result & Risk		Optimal Moderate High		Units —	Result & Risk	
	Optimal	Non-Optimal	Орсина	inouel ate	riigii	Units	
INFLAMMATION							
ADMA (Asymmetric	01		100	100 100	400		
dimethylarginine)	91		<100	100-123	>123	ng/mL	
SDMA (Symmetric	06			70.405			
dimothylargining)	96			73-135		ng/mL	

For details on reference ranges please refer to the reference range/comment section of the report.

**Medical Information For Healthcare Providers:** If you have questions about any of the tests in our Cardio IQ offering, please call Client Services at our Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence. They can be reached at 866.358.9828, option 1 to arrange a consult with our clinical education team.



Patient Information	Specimen Information	Client Information		

**Reference Range/Comments** 

Analyte Name	In Range	Out Range	Reference Range	Lab
ADMA	91		<100 ng/mL	Z4M

Elevated ADMA levels are associated with significant subclinical atherosclerosis while elevated SDMA levels are associated with kidney function and strongly correlate with reduced eGFR. Available prospective studies suggest an increased risk of cardiovascular disease with higher ADMA concentrations (1). Based on an internal reference range study using 180 'apparently healthy,' non-smoking donors, CHL has defined the following cut-offs for ADMA: A cut-off of <100 ng/mL defines an 'apparently healthy' population at optimal relative risk for a cardiovascular event, 100-123 ng/mL defines a population at moderate relative risk for a cardiovascular event, and >123 ng/mL defines a high relative risk population. (Reference: 1-Willeit P. et al. J Am Heart Assoc. 2015; 4: e001833). This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.



